Amrinone, also known as inamrinone, and sold as Inocor, is a pyridine phosphodiesterase 3 inhibitor. [1] It is a drug that may improve the prognosis in patients with congestive heart failure. [2] Amrinone has been shown to increase the contractions initiated in the heart by high-gain calcium induced calcium release (CICR). [3]

2024年2月29日 · Inamrinone, also known as amrinone, is a drug that increases cardiac output through its positive inotropic and vasodilatory effects. It is prescribed for the short-term management of congestive heart failure, relieving symptoms of CHF such as fatigue, weakness, edema, dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.

2007年7月24日 · Amrinone is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.

Inamrinone is a prescription medication used for the treatment of congestive heart failure.

2024年3月25日 · Inamrinone Injection USP represents a new class of cardiac inotropic agents distinct from digitalis glycosides or catecholamines. Inamrinone lactate is designated chemically as 5-Amino [3,4'-bipyridin]-6 (1 H)-one 2-hydroxypropanate and has the following structure:

Amrinone is a novel, nonadrenergic cardiac stimulant that improves myocardial contractility while inducing vasodilation.

Medscape - Indication-specific dosing for amrinone (inamrinone), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost...

2022年9月8日 · Amrinone is an Inotropic agent belonging to Phosphodiesterase Enzyme Inhibitor. Amrinone is approved for the treatment of the short-term management of congestive heart failure, relieving symptoms of the condition such as fatigue, weakness, edema, dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.

Amrinone is a positive inotropic agent and phosphodiesterase inhibitor used in the treatment of congestive Cardiac failure. Now a day Amrinone is not used because of toxicity effect; long term uses shown increase mortality. Milrinone : 5 μg/kg IV bolus injection followed by 2-20 μg/kg/min infusion. Vesnarinone : 60 mg/day orally.

Amrinone is a 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.